Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

PHASE2TerminatedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

May 9, 2025

Study Completion Date

May 9, 2025

Conditions

COVID-19

Interventions

DRUG

NP-101

NP-101 is an organically derived, GMP manufactured product covered under IND #152687.

OTHER

Placebo

Identical placebo

Trial Locations (4)

L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator, Miami

Research Network America, Berwyn

Clinical Trial Network, Houston

Pearland Family Wellness Clinic, Pearland